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Abstract: 
 
Cancer immunotherapy has proven to be a potent treatment modality. Although often 
successful in generating antitumor immune responses, cancer immunotherapy is frequently 
hindered by tumor immune-escape mechanisms. Among immune suppressive strategies within 
the tumor microenvironment, suppressive immune regulatory cells play a key role in promoting 
tumor progression through inhibiting the effector arm of the immune response. Targeting these 
suppressive cells can greatly enhance antitumor immune therapies, hence augmenting a highly 
effective therapeutic antitumor response. Several approaches are being tested to enhance the 
effector arm of the immune system while simultaneously inhibiting the suppressor arm. Some 
of these approaches are none other than traditional drugs repurposed as immune modulators. 
Cyclophosphamide, an old school chemotherapeutic agent used across a wide range of 
malignancies, was found to be a potent immune modulator that targets suppressive regulatory 
immune cells within the tumor microenvironment while enhancing effector cells. Preclinical and 
clinical findings have confirmed the ability of low doses of cyclophosphamide to selectively 
deplete regulatory T cells while enhancing effector and memory cytotoxic T cells within the 
tumor microenvironment. These immune effects translate to suppressed tumor growth and 
enhanced survival, evidence of antitumor therapeutic efficacy.  This article discusses the 
reincarnation of cyclophosphamide as an immune modulator that augments novel 
immunotherapeutic approaches. 
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Introduction 
Immunotherapy is emerging as a potent fourth modality for cancer treatment.  For 
immunotherapy to be successful it requires the generation of effector cells that overcome the 
immune suppressive strategies within the tumor microenvironment. Fundamental components 
of the immune suppressive network are the CD4+Foxp3+ regulatory T cells (Tregs) and the 
Gr1+CD11b+ myeloid-derived suppressor cells (MDSCs).  In addition to their effects on CD8 T cell 
proliferation, these cells secrete cytokines with immune suppressive function such as 
interleukin 10 (IL10) and transforming growth factor beta (TGFβ).   Expression within the tumor 
microenvironment of immune inhibitory checkpoint molecules, such as programed death 
receptor 1 (PD-1) and cytotoxic T lymphocyte associated protein 4 (CTLA-4), is another immune 
escape mechanism.   
 
In addition to the generation of an effective antitumor immune response, targeting these 
suppressive mechanisms is essential for maximizing the efficacy of cancer immunotherapy. 
Many approaches are being investigated to achieve this, some of which come from well known 
old-school drugs that are being repurposed to modulate the immune system for a better 
antitumor outcome. 
 
Cyclophosphamide  
Cyclophosphamide is an alkylating chemotherapeutic agent with strong immunosuppressive 
activity. It was introduced in 1958 and for almost sixty years has been considered the backbone 
of chemotherapeutic regimens in lymphoproliferative diseases as well as a wide range of solid 
tumors. It is also an integral part of the conditioning regimen commonly applied in myelo-
ablative allogeneic stem cell transplantation. It is no wonder that cyclophosphamide is still on 
the World Health Organization's List of Essential Medicines. 
Depending on the dose of administration, cyclophosphamide affects tumors either through 
direct cytotoxic activity or through immune-enhancing mechanisms. Administering 
cyclophosphamide in high doses is cytotoxic, due to its activity as an alkylating agent, which 
leads to inhibition of DNA replication and apoptosis of both tumor and lymphoid cells. This 
cytotoxic effect on lymphoid cells is observed in actively replicating as well as resting, non-
replicating, lymphocytes (1). Therefore, apart from its role as a potent chemotherapeutic agent, 
cyclophosphamide has gained attraction as an immune suppressive treatment in many 
autoimmune disorders, such as vasculitis, systemic lupus erythematosus, and chronic graft-
versus-host disease in recipients of allogeneic stem cell transplants.  Its use in haploidentical 
allogeneic transplant regimens in the treatment of hematologic malignancies has revived the 
use of this strategy and overcome the barriers that exist for many populations to undergo this 
treatment. 
Cyclophosphamide as an immune modulator 
The dose, timing, and sequence of cyclophosphamide administration play major roles in its 
effect on the immune system (Figure 1). As outlined above, high doses of cyclophosphamide 
lead to the nonspecific depletion of immune cells and are therefore used for inducing 
lymphodepletion before adoptive cell transfer, conditioning patients before allogeneic stem cell 
transplantation, as well as chemotherapeutic approaches in aggressive types of 
lymphoproliferative disorders. On the other hand, low doses of cyclophosphamide can have 
antitumor effects by enhancing the immune response. Low doses of cyclophosphamide are 
effective in treating tumors in immune competent, but not nude, mice, indicating that the 
effect of low-dose cyclophosphamide is immune mediated, whereas high-dose led to antitumor 
responses in both types of mice (2).  High doses of cyclophosphamide have also been found to 
decrease lymphocyte infiltration into tumors, whereas low doses leads to higher lymphocyte 
infiltration (2).  Additionally, low dose cyclophosphamide enhances vaccine induced immune 
responses, whereas higher doses impeded vaccination (3).  
How does cyclophosphamide enhance the immune response? 
Low doses of cyclophosphamide enhance immune responses through affecting an array of 
immune cells within the tumor microenvironment. Its effects simultaneously improve the 
effector and inhibit the suppressive arm of the antitumor immune response. 
The effect of cyclophosphamide on Tregs 
Tregs are a fundamental component of immune suppressive mechanisms of tumors; Treg 
depletion enhances antitumor immunity and promotes tumor regression (4, 5). Therefore, 
several approaches have been studied to target Tregs, including our group’s use of PI3K/Akt 
pathway inhibitors to selectively and effectively target Tregs, which has translated into 
therapeutic efficacy in murine tumor models (5).  
Low dose cyclophosphamide (given in single or metronomic (repeated) doses), is associated 
with a temporary reduction in both the number and function of Tregs within the tumor 
microenvironment, its associated lymph nodes, and peripheral blood (6-8). This results in 
enhancing antitumor immune responses when used alone or in combination with cancer 
immunotherapies (6, 9, 10). We and others have demonstrated in mice that single-dose 
cyclophosphamide induced apoptosis in Tregs starting 24 hours after the exposure, with a nadir 
at 3-4 days and full reconstitution reaching pretreatment numbers within 10 days (6). 
In humans, the effect of administration of metronomic cyclophosphamide can selectively 
deplete Tregs and restore both T and NK cell function in advanced cancer patients, in which 
both the numbers and function of Tregs were inhibited (11). In patients with metastatic breast 
cancer, a transient but significant decrease in Treg numbers was observed accompanied by an 
increase in tumor specific T cells (12). Total reconstruction of Tregs follows the prolonged 
metronomic treatment with cyclophosphamide in humans, due to the enhanced proliferation 
of Tregs that maintains their suppressive ability (12).  
Low dose cyclophosphamide has been tested in animal models as part of combination 
immunotherapy with immune therapeutic agents, including different vaccines and immune 
checkpoint inhibitors. We found in a murine tumor model that adding a single dose of 
cyclophosphamide to a combination of HPV16-E6 peptide vaccine with PD-1 binding antibody 
leads to significant enhancement of antitumor therapeutic efficacy and survival. Tumor 
infiltrating Tregs decreased significantly, while infiltrating cytotoxic CD8+ T cells and effector 
CD4+Foxp3– T cells increased significantly, yielding an enhanced antigen-speciﬁc immune 
response (9).  This was further confirmed in a murine model of pancreatic ductal 
adenocarcinoma: adding low-dose cyclophosphamide to the combination of PD-1 antibody with 
GVAX (granulocyte-macrophage colony-stimulating factor–secreting allogeneic pancreatic 
tumor cells) vaccine improved survival. This was a result of enhancing tumor-specific CD8 T cell 
number and activity with PD-1 blockade and suppressing Tregs through low-dose 
cyclophosphamide (13). Similar results were obtained in a prostate cancer murine model 
treated with a different checkpoint inhibitor, antiCTLA-4 antibody, combined with GVAX. 
Although effector CD8 T cells were significantly enhanced with the dual combination, adding 
low dose cyclophosphamide enhanced the therapeutic efficacy by a transient depletion of Tregs 
(14). A photodynamic therapy–generated cancer vaccine was tested in combination with low 
dose cyclophosphamide in a murine tumor model, which found that cyclophosphamide 
enhanced the vaccine’s efficacy by reducing the number of Tregs (15). 
Several mechanisms were proposed for cyclophosphamide mediated Tregs depletion, and loss 
of function (Figure 2A).   
The ability of Tregs to detoxify cyclophosphamide metabolites is impaired, rendering them 
more prone to its cytotoxic effects than other T cells.  Tregs express more CD39, an ectoenzyme 
that hydrolyses extracellular ATP to ADP, causing the efflux and loss of intracellular ATP and 
resulting in less intracellular ATP in comparison to conventional T cells.  Low ATP reduces the 
concentration of the antioxidant glutathione and the cells’ ability to detoxify metabolites (16). 
Tregs also lack expression of the ATP-binding cassette (ABC) transporter B1, which extrudes 
drugs and metabolites from cells. This makes Tregs more susceptible to cyclophosphamide (17).  
CD39 expressing Tregs are associated with increased expression of tumour necrosis factor 
receptor (TNFR2) (18), which is expressed in one of the maximally suppressive Treg phenotypes. 
Interestingly, Tregs expressing TNFR2 and Inducible T-cell costimulator (ICOS) were found to be 
highly susceptible to cyclophosphamide (19).   
In addition to its cytotoxic effect, cyclophosphamide was also reported to inhibit the 
proliferation and the function of Tregs through the downregulation of glucocorticoid-induced 
tumor necrosis factor receptor (TNFR)-related protein (GITR) and Foxp3 (6). Both GITR and 
Foxp3 are important molecules for the suppressive function of Tregs.  GITR acts as a Treg co-
stimulatory molecule that enhances Treg proliferation upon binding to its ligand, and Foxp3 
regulates the transcription of many factors involved in Tregs’ suppressive function. Hence, once 
downregulated by cyclophosphamide, Treg function and proliferation are impaired, leading to a 
reduction in their numbers within the tumor.  
 
The effect of cyclophosphamide on effector T cells 
Low doses of cyclophosphamide can enhance the number and cytotoxic function of effector T 
cells. The combination of metronomic cyclophosphamide with a DepoVax vaccine containing 
HPV16E7 peptide targeting an HPV16-induced murine tumor model led to a sustainable 
antitumor effect. This resulted from the selective lymphodepletion ability of cyclophosphamide 
resulting in the preservation of vaccine-induced CD8 T cells and the subsequent enhancement 
of their cytotoxic ability (20). Additionally, low-dose cyclophosphamide can augment the 
memory phenotypes of CD4 and CD8 T cells, which are superior mediators of antitumor 
immunity. In a murine prostate cancer model, low-dose cyclophosphamide greatly enhanced 
the generation of memory and effector CD4 and CD8 T cells when combined with cell-based 
vaccines encoding hyper-IL6 and hyper-IL11 (21). Cyclophosphamide also has a great effect on 
the phenotype of T cells, especially switching the Treg/Th17 balance to a less suppressive Th17 
phenotype. Pancreatic cancer–bearing mice were treated with mHSP65-TTL vaccine (mixed 
recombinant mycobacterial heat-shock protein 65 and pancreatic cancer tissue lysate) in 
combination with a low dose of cyclophosphamide. Cyclophosphamide alone or in combination 
with mHSP65-TTL upregulated mRNA expressions of RORγt (22), suggesting an enhancement of 
the Th17 phenotype. 
Although the effect that cyclophosphamide has on effector cells is an expected outcome, given 
cyclophosphamide’s depletion of Tregs, several mechanisms were put forward to explain this 
enhancement of effector cells (Figure 2B).  
Cyclophosphamide can directly enhance the proliferation of effector T cells (11, 12). Effector T 
cells released from Treg suppression, significantly increase their numbers within the tumor 
microenvironment. Cyclophosphamide’s effect is also due to the polarization of T cells into the 
more effective antitumor phenotypes (Th1, Th17, and memory CD8 T cells). Low doses of 
cyclophosphamide were associated with a switch to the secretion of Th1 cytokines [interferon 
gamma (INF γ) and Interleukin 2 (IL2)] instead of Th2 associated cytokines [interleukin 4 (IL4) 
and IL 10] (23, 24), which favors a positive antitumor immune response. Evidence for Th17 
polarization upon cyclophosphamide administration is provided by the increase in interleukin 
17 (IL17) secretion (25) and upregulation of RORγt (22). Cyclophosphamide inhibits nitric oxide 
synthase (iNOS), an enzyme that leads to the generation of nitric oxide (NO).  Low NO helps 
convert cyclic guanosin-5-triphosphate into 3’,5’-cyclic guanosine monophosphate (cGMP). 
Increased cGMP within CD4 cells leads to the induction of IL12 receptor β2 (IL12Rβ2), allowing 
induction of Th1 differentiation by IL12 (26).  
The effect of cyclophosphamide extends to cytotoxic CD8 T cells. IL2 secretion, which is 
associated with cyclophosphamide administration, enhances the memory phenotype of 
cytotoxic CD8 T cells (23). Additionally, the decrease in nitric oxide, outlined above, leads to 
enhancement of memory CD8 T cells (27). Memory CD8 T cells are superior mediators of 
antitumor immune responses due to their enhanced proliferative and cytotoxic abilities (28). 
This explains, at least in part, the enhanced antitumor immune response associated with 
cyclophosphamide treatment. 
The effect of cyclophosphamide on MDSCs 
Despite the effect low-dose cyclophosphamide has in reducing the number and function of 
Tregs, it has been reported to increase the number of suppressive MDSCs (Gr1+CD11b+) within 
the tumor microenvironment. It is speculated that this phenomenon is due to the increased 
production of inflammatory mediators, such as granulocyte-macrophage colony-stimulating 
factor (GM-CSF), interleukin 1β (IL1β), interleukin 5 (IL5), IL10, IFNγ, and tumor necrosis factor 
alpha (TNFα) (Figure 2B). These chemokines induce MDSC expansion and activation that may 
eventuate their accumulation; which when coupled with the increased nitric oxide production 
could potentially lead to the inhibition of effector T-cell proliferation (29).  It is apparent 
though, from the enhanced therapeutic efficacy reported in most studies with significant 
increases in the number of cytotoxic effector T cells, that the potential inhibition of effector T 
cells by MDSCs might not significantly affect antitumor cytotoxicity (9, 10).  
 
Cyclophosphamide: an immune modulator in the clinic 
It has been over 30 years since North showed that cyclophosphamide enhances the effect of 
adoptively transferred T cells to control tumors in mice, but clinical translation of these results 
has been difficult (30).  While reviewing all trials is outside the scope of this article, we will 
summarize some of the current ongoing activities in this area. The best evidence for 
cyclophosphamide’s beneficial enhancement of tumor immunity was observed in a trial of 
multipeptide vaccines and GM-CSF in patients with advanced renal cell cancer. The addition of 
cyclophosphamide 3 days before vaccination reduced Treg cells in the blood and improved 
overall survival. Progression-free survival was not impacted, as has been observed in other 
vaccine trials (31).    
Several vaccine platforms were tested in combination with cyclophosphamide. In patients with 
advanced melanoma, pre-treatment with metronomic low-dose cyclophosphamide enhanced 
antigen-specific immune responses when combined with NY-ESO-1 vaccine. Although a 
reduction in Treg numbers was not detected two weeks after cyclophosphamide treatment, an 
earlier transient drop in their number is speculated (32). Metronomic doses of 
cyclophosphamide were also tested in combination with a survivin HLA class I peptide vaccine 
using DepoVax™ platform (DPX-Survivac) in ovarian cancer patients. Antigen-specific immune 
responses were observed in the form of memory and effector CD4 and CD8 T cells. Transient 
drop in Treg numbers was observed and a drop in Treg functionality is speculated to have aided 
in the enhancement of the antitumor immune response (33). 
In patients with pancreatic adenocarcinoma, low dose cyclophosphamide was used to target 
Treg cells in combination with two different vaccines; GVAX, or the Listeria-based vaccine CRS-
207, which expresses mesothelin (34). In another study, pancreatic adenocarcinoma patients 
were given the GVAX vaccine in combination with low-dose cyclophosphamide. Intratumoral 
tertiary lymphoid aggregates were observed and microarray analysis identified a suppressed 
Treg pathway and an enhanced Th17 pathway, which were associated with enhanced 
antitumor immune responses and survival. In addition, an upregulation of the PD-1–PD-L1 
pathway was observed after treatment suggesting a potential for combination with immune 
checkpoint inhibitors (35). 
Currently multiple clinical trials using cyclophosphamide as a cancer therapy adjuvant, and 
specifically as an immune modulator, are ongoing. These include combinations with various 
vaccines, CAR-T cells, SMAC mimetic LCL161 and immune checkpoint inhibitors.  The results of 
these studies are eagerly awaited.  The critical parameter for evaluation in determining how to 
maximize the benefit of cyclophosphamide remains to be determined.  Changes in Treg number 
or function, antigen-specific T -cell response, or changes in MDSCs are potential endpoints for 
analysis, but ultimately, improvement in patient survival is most important.     
 
Final note 
 
Cyclophosphamide is an economically attractive chemotherapeutic drug that is FDA-approved 
for clinical treatment of a wide range of cancers, which can be repurposed to augment novel 
immunotherapeutic agents.  Preclinical and clinical studies have already shown great promise 
for the combination of this old-school chemotherapeutic agent with cancer vaccines and 
immune check point inhibitors. The use of cyclophosphamide, a potent immune modulator, in 
combination with various immunotherapies harbors great potential for enhancing both 
adoptive cell transfer and vaccine-based cancer immunotherapies.  
 
References 
 
 
1. de Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics of 
cyclophosphamide. Clin Pharmacokinet. 2005;44:1135-64. 
2. Motoyoshi Y, Kaminoda K, Saitoh O, Hamasaki K, Nakao K, Ishii N, et al. Different 
mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol Rep. 
2006;16:141-6. 
3. Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, et al. 
Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of 
granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu 
tolerized mice. Cancer Res. 2001;61:3689-97. 
4. Keenan BP, Saenger Y, Kafrouni MI, Leubner A, Lauer P, Maitra A, et al. A Listeria 
Vaccine and Depletion of T-Regulatory Cells Activate Immunity Against Early Stage Pancreatic 
Intraepithelial Neoplasms and Prolong Survival of Mice. Gastroenterology. 2014. 
5. Abu-Eid R, Samara RN, Ozbun L, Abdalla MY, Berzofsky JA, Friedman KM, et al. Selective 
inhibition of regulatory T cells by targeting the PI3K-Akt pathway. Cancer Immunol Res. 
2014;2:1080-9. 
6. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of 
CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose 
cyclophosphamide. Blood. 2005;105:2862-8. 
7. Roux S, Apetoh L, Chalmin F, Ladoire S, Mignot G, Puig PE, et al. CD4+CD25+ Tregs 
control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon 
cancer. J Clin Invest. 2008;118:3751-61. 
8. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, et al. 
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide 
which allows immunotherapy of established tumors to be curative. Eur J Immunol. 
2004;34:336-44. 
9. Mkrtichyan M, Najjar YG, Raulfs EC, Abdalla MY, Samara R, Rotem-Yehudar R, et al. Anti-
PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through 
novel mechanisms. Eur J Immunol. 2011;41:2977-86. 
10. Mkrtichyan M, Najjar YG, Raulfs EC, Liu L, Langerman S, Guittard G, et al. B7-DC-Ig 
enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell 
subsets. J Immunol. 2012;189:2338-47. 
11. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic 
cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T 
and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 
2007;56:641-8. 
12. Ge Y, Domschke C, Stoiber N, Schott S, Heil J, Rom J, et al. Metronomic 
cyclophosphamide treatment in metastasized breast cancer patients: immunological effects 
and clinical outcome. Cancer Immunol Immunother. 2012;61:353-62. 
13. Soares KC, Rucki AA, Wu AA, Olino K, Xiao Q, Chai Y, et al. PD-1/PD-L1 blockade together 
with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. J Immunother. 
2015;38:1-11. 
14. Wada S, Jackson CM, Yoshimura K, Yen HR, Getnet D, Harris TJ, et al. Sequencing CTLA-4 
blockade with cell-based immunotherapy for prostate cancer. J Transl Med. 2013;11:89. 
15. Korbelik M, Banath J, Saw KM. Immunoregulatory Cell Depletion Improves the Efficacy 
of Photodynamic Therapy-Generated Cancer Vaccines. Int J Mol Sci. 2015;16:27005-14. 
16. Zhao J, Cao Y, Lei Z, Yang Z, Zhang B, Huang B. Selective depletion of CD4+CD25+Foxp3+ 
regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP 
levels. Cancer Res. 2010;70:4850-8. 
17. Dimeloe S, Frick C, Fischer M, Gubser PM, Razik L, Bantug GR, et al. Human regulatory T 
cells lack the cyclophosphamide-extruding transporter ABCB1 and are more susceptible to 
cyclophosphamide-induced apoptosis. Eur J Immunol. 2014;44:3614-20. 
18. Govindaraj C, Scalzo-Inguanti K, Madondo M, Hallo J, Flanagan K, Quinn M, et al. 
Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the 
tumor microenvironment. Clin Immunol. 2013;149:97-110. 
19. van der Most RG, Currie AJ, Mahendran S, Prosser A, Darabi A, Robinson BW, et al. 
Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T 
cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective 
chemotherapy. Cancer Immunol Immunother. 2009;58:1219-28. 
20. Weir GM, Hrytsenko O, Stanford MM, Berinstein NL, Karkada M, Liwski RS, et al. 
Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific 
and cytotoxic T-cell mediated antitumor immune response. Oncoimmunology. 2014;3:e953407. 
21. Mackiewicz J, Kotlarski M, Dondajewska E, Nowicka-Kotlarska A, Krokowicz L, 
Kazimierczak U. Cell-based Hyper-interleukin 6 or Hyper-interleukin 11 secreting vaccines 
combined with low dose cyclophosphamide in an orthotopic murine prostate cancer model. 
Contemp Oncol (Pozn). 2015;19:187-94. 
22. Xuan W, Yan Y, Wan M, Wu X, Ji D, Wang L, et al. Antitumor activity of mHSP65-TTL 
enhanced by administration of low dose cyclophosphamide in pancreatic cancer-bearing mice. 
Int Immunopharmacol. 2015;27:95-103. 
23. Schiavoni G, Mattei F, Di Pucchio T, Santini SM, Bracci L, Belardelli F, et al. 
Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T 
lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood. 
2000;95:2024-30. 
24. Matar P, Rozados VR, Gervasoni SI, Scharovsky GO. Th2/Th1 switch induced by a single 
low dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol 
Immunother. 2002;50:588-96. 
25. Viaud S, Flament C, Zoubir M, Pautier P, LeCesne A, Ribrag V, et al. Cyclophosphamide 
induces differentiation of Th17 cells in cancer patients. Cancer Res. 2011;71:661-5. 
26. Niedbala W, Wei XQ, Campbell C, Thomson D, Komai-Koma M, Liew FY. Nitric oxide 
preferentially induces type 1 T cell differentiation by selectively up-regulating IL-12 receptor 
beta 2 expression via cGMP. Proc Natl Acad Sci U S A. 2002;99:16186-91. 
27. Loeffler M, Kruger JA, Reisfeld RA. Immunostimulatory effects of low-dose 
cyclophosphamide are controlled by inducible nitric oxide synthase. Cancer Res. 2005;65:5027-
30. 
28. Abu Eid R, Friedman KM, Mkrtichyan M, Walens A, King W, Janik J, et al. Akt1 and -2 
inhibition diminishes terminal differentiation and enhances central memory CD8 T-cell 
proliferation and survival. Oncoimmunology. 2015;4:e1005448. 
29. Sevko A, Sade-Feldman M, Kanterman J, Michels T, Falk CS, Umansky L, et al. 
Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and 
prevents antitumor response in melanoma. J Invest Dermatol. 2013;133:1610-9. 
30. North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established 
tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med. 1982;155:1063-
74. 
31. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, et al. Multipeptide 
immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates 
with longer patient survival. Nat Med. 2012;18:1254-61. 
32. Klein O, Davis ID, McArthur GA, Chen L, Haydon A, Parente P, et al. Low-dose 
cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX 
vaccine in patients with advanced melanoma. Cancer Immunol Immunother. 2015;64:507-18. 
33. Berinstein NL, Karkada M, Oza AM, Odunsi K, Villella JA, Nemunaitis JJ, et al. Survivin-
targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in 
advanced ovarian cancer patients. Oncoimmunology. 2015;4:e1026529. 
34. Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, et al. Safety and 
survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-
207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015;33:1325-33. 
35. Lutz ER, Wu AA, Bigelow E, Sharma R, Mo G, Soares K, et al. Immunotherapy converts 
nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer 
Immunol Res. 2014;2:616-31. 
 
 
  
Figure Legends: 
Figure 1 
The Immune modulatory effect of cyclophosphamide on T cells. 
When given in high doses, cyclophosphamide leads to nonspecific depletion of T cells. However, 
at low doses, cyclophosphamide exerts a range of effects on different T cell subsets: selective 
depletion of Tregs and inhibition of their suppressive function; switching the secretion of 
cytokines from Th2 to Th1; and enhancement of Th17, memory, and effector CD8 T-cell 
phenotypes. 
 
Figure 2 
A) The mechanisms by which low dose cyclophosphamide inhibits the number and function of 
Tregs. 
B) The mechanisms by which low dose cyclophosphamide modulates different immune cells. 
  
 
  
 
  
 
